Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-16
2008-12-16
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07465737
ABSTRACT:
The invention relates to use of a pyrimidone derivative represented by formula (I)or a salt thereof wherein:X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.
REFERENCES:
patent: WO 00/18758 (2000-04-01), None
patent: WO 02/18386 (2002-03-01), None
Bhat, et al., J. Neurochem., 2004, 89, 1313-1317.
Martinez, et al., Med. Res. Rev., vol. 22, No. 4, 373-384 (2002).
Buée, et al., Brain Res. Rev., 33 (2000) 95-130.
Henriksen, et al., Curr. Drug Targets, 2006, 7 (11), 1435-42 (Abstract).
Gould et al., Curr. Drug Targets, Nov. 7, 2006(11): 1399-409 (Abstract).
Harwood, Curr. Mol. Med., Aug. 2003; 3(5): 472-82.
Zhao, et al., Schizophr. Res., May 2006; 84(1). Epub Apr. 11, 2006 (Abstract).
Gould, Expert Opin. Ther. Targets, Jun. 2006; 10(3):377-92 (Abstract).
Kwok, et al., Annals of Neurology, vol. 58, No. 6, Dec. 2005, pp. 829-839.
Nadri, et al., Schizophrenia Research, 71 (2004), 377-382.
Ciaraldi, et al., Am. J. Physiol. Endocrinol. Metab. 291: E891-E898, 2006.
Bhat, R.V., et. al., Glycogen Synthase Kinase 3: A drug Target for CNS Therapies, Journal of Neurochemistry, vol. 89, (2004), pp. 1313-1317.
Harwood, A.J., et. al., Neurodevelopment and Mood Stabilizers, PubMed abstract on Curr. Mol. Med., Aug. 2003; vol. 3, No. 5 pp. 472-482.
Leclerc, S., et. al., Indirubins Inhibit Glycogen synthase Kinase-3B and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosporylation in alzheimer's Disease , The Journal of Biological Chemistry, vol. 276, No. 1, (2001), pp. 251-260.
Souillac, P., et. al., Characterization of Delivery Systems, Differential Scanning Calorimetry, Encyclopedia of Controlled Drug Delivery, (1999), John Wiley & Sons, pp. 212-227.
Wagman, A.S., et. al., Discovery and Develpoment of GSK3 Inhibitors for the Treatment of Type 2 Diabetes, Current Pharmaceutical Design, (2004) vol. 10, pp. 1105-1137.
Disorders Index of the National Institute of Neurological Disorders and Stroke,, Oct. 2006 http://www.ninds.nih.gov/disorders/disorder—index.htm?css=print.
Lochead Alistair
Nedelec Alain
Saady Mourad
Yaiche Philippe
Berch Mark L
Gupta Balaram
Jaisle Cecilia M
Mitsubishi Pharma Corporation
Sanofi-Aventis
LandOfFree
Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021599